Publications by authors named "Julie Bullock"

Claim this Profile
O
Oncology Combination Drug Development Strategies for Project Optimus.
Timothy A Yap, Julie Bullock, Susan Chong, Megan K Doyle, Azher Hussain

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric oncology drug development and dosage optimization.
S Y Amy Cheung, Justin L Hay, Yu-Wei Lin, Rik de Greef, Julie Bullock

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response of trilaciclib in extensive-stage small cell lung cancer and triple-negative breast cancer.
Chao Li, Benjamin Rich, Julie M Bullock, Olivier Barrière, Jean-Francois Marier

Br J Clin Pharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to adherence to oral drug regimens in oncology and strategies for improvement.
Julie M Bullock

Clin Adv Hematol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study.
Sally A Kinrade, Jay W Mason, Carlos R Sanabria, Craig R Rayner, Julie M Bullock

Clin Transl Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
Julie M Bullock, Tiffany Lin, Sanela Bilic

J Clin Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
Julie M Bullock, Atiqur Rahman, Qi Liu

Clin Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
R Angelo de Claro, Karen M McGinn, Nicole Verdun, Shwu-Luan Lee, Haw-Jyh Chiu, Julie Bullock

Clin Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Hyon-Zu Lee, Virginia E Kwitkowski, Pedro L Del Valle, M Stacey Ricci, Haleh Saber, Julie Bullock

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Barry W Miller, Donna Przepiorka, R Angelo de Claro, Kyung Lee, Lei Nie, Julie Bullock

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F Zirkelbach, Liang Zhao, Julie Bullock

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Hyon-Zu Lee, Barry W Miller, Virginia E Kwitkowski, Stacey Ricci, Pedro DelValle, Julie Bullock

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Firoozeh Alvandi, Virginia E Kwitkowski, Chia-Wen Ko, Mark D Rothmann, Stacey Ricci, Julie Bullock

Oncologist· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Thomas M Herndon, Albert Deisseroth, Edvardas Kaminskas, Robert C Kane, Kallappa M Koti, Julie Bullock

Clin Cancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
R Angelo de Claro, Karen McGinn, Virginia Kwitkowski, Julie Bullock, Aakanksha Khandelwal

Clin Cancer Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Albert Deisseroth, Edvardas Kaminskas, Joseph Grillo, Wei Chen, Haleh Saber, Julie Bullock

Clin Cancer Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.
Joseph A Grillo, Ping Zhao, Julie Bullock, Brian P Booth, Min Lu

Biopharm Drug Dispos· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.
Shakun M Malik, Ke Liu, Xu Qiang, Rajeshwari Sridhara, Shenghui Tang, Julie Bullock

Clin Cancer Res· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparing pharmacy graduates for traditional and emerging career opportunities.
Gayle A Brazeau, Susan M Meyer, Michele Belsey, Edward M Bednarczyk, Sanela Bilic, Julie Bullock

Am J Pharm Educ· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Robert J Lechleider, Edvardas Kaminskas, Xiaoping Jiang, Robeena Aziz, Julie Bullock

Clin Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Michael Brave, Vicki Goodman, Edvardas Kaminskas, Ann Farrell, William Timmer, Julie Bullock

Clin Cancer Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Yan-Ling He, Yibin Wang, Julie M Bullock, Carolyn F Deacon, Jens Juul Holst

J Clin Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation.
Julie M Bullock, Patrick F Smith, Brent M Booker, John Loughner, Donna Capozzi

Ther Drug Monit· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
Brent M Booker, Patrick F Smith, Alan Forrest, Julie Bullock, Pamela Kelchlin

Antimicrob Agents Chemother· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
Patrick Smith, Julie M Bullock, Brent M Booker, Curtis E Haas, Charles S Berenson

Pharmacotherapy· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis